SCHEMBL17409802

SCHEMBL17409802

Cc1ccc(CN2CCNC(=O)C2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
FGFR1 P11362 2/20 0.41
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
GRM5 P41594 1/20 0.40
EED O75530 1/20 0.39
SUZ12 Q15022 1/20 0.39
EZH2 Q15910 1/20 0.39
SCN9A Q15858 2/20 0.39
MDM2 Q00987 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PDE10A Q9Y233 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
SLC2A1 P11166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15986729 0.84 HRH3 (0.47) PDCD1CD274KMT2AATMGRM5
SCHEMBL20456859 0.83 EED (0.41) PDCD1CD274KMT2AATMGRM5
SCHEMBL15206345 0.83 KMT2A (0.40) PDCD1CD274KMT2AATMGRM5
SCHEMBL17403599 0.83 SCN9A (0.41) PDCD1CD274FGFR1KMT2AATM
SCHEMBL17403567 0.83 SCN9A (0.45) PDCD1CD274KMT2AATMGRM5
SCHEMBL20160684 0.82 CXCR4 (0.49) KMT2ASCN9AKDM5CKDM4CALDH1A1
SCHEMBL22175530 0.78 KMT2A (0.54) KMT2ASMN1; SMN2NPSR1KDM4EALDH1A1
SCHEMBL17468364 0.78 CXCR4 (0.55) KMT2AATMGRM5SMN1; SMN2KDM4E
SCHEMBL23206047 0.77 HRH3 (0.43) EEDSUZ12EZH2MDM2NPSR1
SCHEMBL18291554 0.75 GRM5 (0.47) PDCD1CD274FGFR1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433622-B2 Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-06 US disclosed
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS TBK1, TBKBP1, TYMS PDCD1 1533/4885CD274 2568/4885FGFR1 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.